This disclosure provides replication-incompetent adenoviral vectors useful in vaccine development and gene therapy. The disclosed vectors comprise a selective deletion of E3 and are particularly useful for preparation of vaccines development and for gene therapy using toxic transgene products that result in vector instability that occurs when the entire E3 domain is deleted.

This disclosure provides replication-incompetent adenoviral vectors useful in vaccine development and gene therapy. The disclosed vectors comprise a selective deletion of E3 and are particularly useful for preparation of vaccines development and for gene therapy using toxic transgene products that result in vector instability that occurs when the entire E3 domain is deleted.

Aspects of the disclosure relate to constructs comprising one or more Ca.sub.v3.2 inhibitory polypeptide that blocks Ca.sub.v3.2 T-type calcium channel activity and nociceptive dorsal root ganglion (DRG) neuron excitation. Also provided herein are methods for treating pain in a subject in need thereof. In particular, provided herein are methods comprising administering Ca.sub.v3.2 inhibitory peptide constructs to a dorsal root ganglion of the subject, whereby expression of the Ca.sub.v3.2 inhibitory polypeptides partially or fully inhibits Ca.sub.v3.2 T-type calcium channel activity in the DRG.

Aspects of the disclosure relate to constructs comprising one or more Ca.sub.v3.2 inhibitory polypeptide that blocks Ca.sub.v3.2 T-type calcium channel activity and nociceptive dorsal root ganglion (DRG) neuron excitation. Also provided herein are methods for treating pain in a subject in need thereof. In particular, provided herein are methods comprising administering Ca.sub.v3.2 inhibitory peptide constructs to a dorsal root ganglion of the subject, whereby expression of the Ca.sub.v3.2 inhibitory polypeptides partially or fully inhibits Ca.sub.v3.2 T-type calcium channel activity in the DRG.

The present invention is directed to viral vectors and methods of their production and use.

The present invention is directed to viral vectors and methods of their production and use.

Methods of assembling modified adenoviruses, libraries of adenoviral gene modules and compositions thereof are provided herein.

Methods of assembling modified adenoviruses, libraries of adenoviral gene modules and compositions thereof are provided herein.

The present disclosure relates to anti-mullerian hormone (AMH) analogues, more particularly AMH analogues which are agonists of the AMH type II receptor (AMHR2). More particularly, the present disclosure relates to AMH analogues having a modification present within one or more of amino acid residues 533 to 548 of SEQ ID NO:1.

The present disclosure relates to anti-mullerian hormone (AMH) analogues, more particularly AMH analogues which are agonists of the AMH type II receptor (AMHR2). More particularly, the present disclosure relates to AMH analogues having a modification present within one or more of amino acid residues 533 to 548 of SEQ ID NO:1.